ClinicalTrials.gg
RecruitingNCT04395196Updated Jul 9, 2026

RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure

A Phase 2 interventional study of Choline bitartrate and Placebo in Fetal Alcohol Spectrum Disorders and Fetal Alcohol Syndrome, sponsored by Wayne State University. Recruiting at 1 site in South Africa. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Wayne State University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Although the adverse effects associated with prenatal alcohol exposure (PAE) are well known, many women continue to drink heavily during pregnancy, putting their infants at risk for fetal alcohol spectrum disorders. Animal studies have shown that choline supplementation can mitigate effects of PAE on growth and development. Choline, an essential nutrient, serves as a methyl-group donor for DNA methylation and is a constituent of the neurotransmitter acetylcholine and a precursor to major components of cell membranes. In an R21 feasibility trial, 70 heavy drinkers were randomly assigned to receive a daily dose of 2g of choline or a placebo from initiation of antenatal care to delivery in Cape Town, South Africa, where the incidence of heavy drinking during pregnancy and fetal alcohol syndrome are among the highest in the world. When compared with infants in the placebo arm, infants in the choline-treated arm were more likely to meet criterion for eyeblink conditioning, demonstrated markedly better recognition memory on the Fagan Test of Infant Intelligence, which is known to have predictive validity for school-age IQ, and had better postnatal gains in weight and head circumference. Key features of this study included the higher choline dose (4.4 times adequate intake (AI), compared to 1.7-2.5 in previous human studies) and initiation of treatment early in pregnancy. We are now conducting a fully-powered, double-blind, randomized, placebo-controlled choline supplementation trial in heavy drinking pregnant women from a rural community in South Africa (1) to assess the effectiveness of maternal choline supplementation during pregnancy to mitigate effects of PAE on three primary outcomes: infant recognition memory and postnatal growth restriction (weight and head circumference); (2) to assess the efficacy of this supplementation for mitigating alcohol effects on the following secondary outcomes: infant eyeblink conditioning, postnatal length, and information processing speed; (3) to use innovative methods in causal inference analysis to examine protocol adherence as an important source of variation in treatment efficacy and to identify sociodemographic factors associated with non-compliance in order to facilitate implementation of the intervention protocol in clinical settings; and (4) in exploratory analyses, to examine whether maternal choline supplementation is particularly effective in women with lower dietary choline intake or poor nutritional status.

02

Conditions studied

  • Fetal Alcohol Spectrum Disorders
  • Fetal Alcohol Syndrome

Keywords

  • Prenatal Alcohol Exposure
  • Choline Supplementation
  • Infant Neurodevelopment
  • Growth
03

In context

Fetal Alcohol Spectrum Disorders

65 studies on the registry are indexed under Fetal Alcohol Spectrum Disorders; 13 are open to participants now.

This study's planned enrollment of 288 is above the median of 74 across 57 interventional studies indexed under Fetal Alcohol Spectrum Disorders.

Browse Fetal Alcohol Spectrum Disorders studies →

Lead sponsor

Wayne State University is the lead sponsor of 231 studies on the registry; 36 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 4 (24%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 yr
  • ≤20 wk gestation
  • Singleton pregnancy
  • Currently heavy drinking (average of ≥15 ml AA/day or binge drinking (≥4 standard drinks/occasion) on at least 1.5 occasions/month on average since becoming pregnant)
  • Current choline dietary intake \<1 g/day
  • Language fluency in English or Afrikaans

Exclusion criteria

Exclusion Criteria:

  • Use of methamphetamine or other illicit drugs other than marijuana during the past year
  • positive
  • Pharmacologic treatment for a serious pre-existing medical condition (e.g., diabetes, hypertension, epilepsy, or cardiac problems)
  • Having another child enrolled in the trial from a previous pregnancy
  • Plans for mother or child to move away from the area prior to study completion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
288 participants (estimated)

Study arms

  • Active comparator
    High-dose choline supplementation

    2 g choline cation

    Dietary Supplement: Choline bitartrate

  • Placebo comparator
    Placebo

    Placebo identical to active treatment in appearance, taste, and smell.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementCholineStudies of CholineCholine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Provided in beverage form

  • Dietary supplementPlacebo

    Provided in beverage form

06

What researchers measure

Primary outcomes

  1. Infant recognition memory

    Novelty preference from the Fagan Test of Infant Intelligence

    Time frame: 12 months

  2. Postnatal infant weight gain

    Time frame: 6.5 months

  3. Postnatal growth in infant head circumference

    Time frame: 6.5 months

Secondary outcomes

  1. Infant information processing speed

    Processing speed on the Fagan Test of Infant Intelligence

    Time frame: 12 months

  2. Postnatal growth in infant length

    Time frame: 6.5 months

07

Study locations

1 of 1 sites recruiting
  • University of Cape Town Faculty of Health Sciences
    Cape Town, Western Cape 7925, South Africa
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — We will make data collected in this study publicly available in accordance with the policies laid out in the NIH/National Institute on Alcohol Abuse and Alcoholism (NIAAA) Data-Sharing Policy for Human Subjects Grants Research Funded by the NIAAA (NOT-AA-18-010; https://grants.nih.gov/grants/guide/notice-files/NOT-AA-18- 010.html). Individual participant data relating to the chief aims of this study data obtained with NIAAA funding will be uploaded to the NIAAA Data Archive (NIAAADA). Only de-identified data will be available to the NIAAADA. A data dictionary will also be available.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Per NIAAA policies, data will be made available for sharing with researchers 2 years after the end of the grant or 2 years after the end date of a no-cost-extension, if issued. The end date for data requests will be determined by NIAAA policies.

Access criteria: Per NIAAA guidelines, for research purposes, "investigators at institutions with a Federal Wide Assurance (FWA) will be able to gain access to NIAAADA data by submitting a data access request in accordance with applicable NIAAADA policies (see https://ndar.nih.gov/access.html for sample policies). Data requests will be reviewed and granted by an NIAAA Data Access Committee." The study protocol, statistical analysis plan, and analytic code may be shared by requests to PI Sandra W. Jacobson, PhD.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Oct 2027, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2020
First posted
May 20, 2020
StartActual
Apr 13, 2023
Primary completionEst.
Oct 15, 2027
CompletionEst.
May 15, 2028
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04395196
Responsible party
Sandra W. Jacobson, Ph.D (Professor, Wayne State University) — Principal investigator
First posted
May 20, 2020
Start date
Apr 13, 2023
Primary completion
Oct 15, 2027 (estimated)
Completion
May 15, 2028 (estimated)
Last update
Jul 9, 2026

Study contacts

R. Colin Carter, MD, MMSc
Contact
rcc2142@cumc.columbia.edu
+16176949902
Sandra W Jacobson, PhD
Contact
sandra.jacobson@wayne.edu
+13139935454
Sandra W Jacobson, PhD
principal investigator · Wayne State University
Joseph L Jacobson, PhD
principal investigator · Wayne State University
Ernesta M Meintjes, PhD
principal investigator · University of Cape Town Faculty of Health Sciences
R. Colin Carter, MD, MMSc
principal investigator · Columbia University Vagelos College of Physicians and Surgeons

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Choline

Start the discussion